

**VPS4A antibody - N-terminal region**  
**Rabbit Polyclonal Antibody**  
**Catalog # AI13710****Specification**

---

**VPS4A antibody - N-terminal region - Product Information**

Application	WB
Primary Accession	<a href="#">O9UN37</a>
Other Accession	<a href="#">NM_013245</a> , <a href="#">NP_037377</a>
Reactivity	Human, Mouse, Rat, Rabbit, Horse, Bovine, Guinea Pig, Dog
Predicted Host	Human, Mouse, Rat, Rabbit, Bovine, Dog
Clonality	Rabbit
Calculated MW	Polyclonal 49kDa KDa

**VPS4A antibody - N-terminal region - Additional Information****Gene ID** 27183**Alias Symbol** FLJ22197, SKD1, SKD2, VPS4, VPS4-1, SKD1A**Other Names**

Vacuolar protein sorting-associated protein 4A, 3.6.4.6, Protein SKD2, VPS4-1, hVPS4, VPS4A {ECO:0000312|EMBL:AAG01470.1}

**Format**

Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose.

**Reconstitution & Storage**

Add 50 ul of distilled water. Final anti-VPS4A antibody concentration is 1 mg/ml in PBS buffer with 2% sucrose. For longer periods of storage, store at 20°C. Avoid repeat freeze-thaw cycles.

**Precautions**

VPS4A antibody - N-terminal region is for research use only and not for use in diagnostic or therapeutic procedures.

**VPS4A antibody - N-terminal region - Protein Information****Name** VPS4A {ECO:0000312|EMBL:AAG01470.1}**Function**

Involved in late steps of the endosomal multivesicular bodies (MVB) pathway. Recognizes membrane-associated ESCRT-III assemblies and catalyzes their disassembly, possibly in combination with membrane fission. Redistributes the ESCRT-III components to the cytoplasm for further rounds of MVB sorting. MVBs contain intraluminal vesicles (ILVs) that are generated by invagination and scission from the limiting membrane of the endosome and mostly are delivered to lysosomes enabling degradation of membrane proteins, such as stimulated growth factor

receptors, lysosomal enzymes and lipids. It is required for proper accomplishment of various processes including the regulation of endosome size, primary cilium organization, mitotic spindle organization, chromosome segregation, and nuclear envelope sealing and spindle disassembly during anaphase (PubMed: [33186545](http://www.uniprot.org/citations/33186545)). Involved in cytokinesis: retained at the midbody by ZFYVE19/ANCHR and CHMP4C until abscission checkpoint signaling is terminated at late cytokinesis. It is then released following dephosphorylation of CHMP4C, leading to abscission (PubMed: [24814515](http://www.uniprot.org/citations/24814515)). VPS4A/B are required for the exosomal release of SDCBP, CD63 and syndecan (PubMed: [22660413](http://www.uniprot.org/citations/22660413)). Critical for normal erythroblast cytokinesis and correct erythropoiesis (PubMed: [33186543](http://www.uniprot.org/citations/33186543)).

### Cellular Location

Late endosome membrane {ECO:0000250|UniProtKB:Q8VEJ9}; Peripheral membrane protein {ECO:0000250|UniProtKB:Q8VEJ9}. Midbody Cytoplasm, cytoskeleton, spindle  
Note=Membrane-associated in the prevacuolar endosomal compartment Localizes to the midbody of dividing cells, interaction with ZFYVE19/ANCHR mediates retention at midbody (PubMed:24814515) Localized in two distinct rings on either side of the Flemming body

### Tissue Location


Ubiquitously expressed.

## VPS4A antibody - N-terminal region - Protocols

Provided below are standard protocols that you may find useful for product applications.


- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

## VPS4A antibody - N-terminal region - Images




WB Suggested Anti-VPS4A Antibody Titration: 0.2-1 µg/ml  
ELISA Titer: 1:312500  
Positive Control: Human Muscle

### VPS4A



Host: Rabbit  
Target Name: VPS4A  
Sample Tissue: Human Fetal Heart  
Antibody Dilution: 1.0 µg/ml

### VPS4A



Host: Rabbit  
Target Name: VPS4A  
Sample Tissue: Human Fetal Lung  
Antibody Dilution: 1.0 µg/ml